Provided herein, among other things, is a method for predicting how a patient responds to immunotherapy. In some embodiments, the method may comprise: performing a multiplexed binding assay on a tissue section of a tumor obtained from a cancer patient to identify at least cancer cells, effector immune cells and immunosuppressive cells in the tissue section; measuring, for each cell of a plurality of the effector immune cells: (i) the physical distance to its most proximal cancer cell; and (ii) the physical distances to its most proximal immunosuppressive cell; and calculating, for each of the effector immune cells analyzed, the ratio of the distance measured in step (i) and distance measured in step (ii), wherein the ratio is predictive of the patient's response to immunotherapy. The method may be used to select patients for immunotherapy.

Single-cell analysis of a population of cells reveals cellular genotypes (e.g., single nucleotide variants and copy number variations) and phenotypes (e.g., protein expression) of individual cells. In one scenario, individual cells can be classified according to their respective genotypes and phenotypes. In one scenario, genotypes and phenotypes of all cells in the population are informative for identifying subpopulations of cells, thereby revealing intra-population heterogeneity. The identification of subpopulations of cells is informative for improving the understanding of cellular biology, especially in the context of diseases such as cancer, and is further informative for the better design of diagnostics and therapies.

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

A lectin-binding substance measurement method is a method for measuring a lectin-binding substance in a sample, and includes a measuring step of bringing a blocked labeled lectin including a water-soluble carrier made of a first water-soluble polymer and a labeling substance and a lectin immobilized on the water-soluble carrier into contact with the sample.

A lectin-binding substance measurement method is a method for measuring a lectin-binding substance in a sample, and includes: a capturing step of bringing a capture carrier including a water-insoluble carrier and a molecule immobilized on the water-insoluble carrier, the molecule being a molecule capable of capturing a lectin-binding substance, into contact with the sample to cause the capture carrier to capture the lectin-binding substance; a washing step of removing contaminants unbound to the capture carrier; a releasing step of releasing the lectin-binding substance from the capture carrier to obtain a prepared sample; and a measuring step of measuring the lectin-binding substance in the prepared sample by using a lectin.

The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.

Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.

The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.

An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.

The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.